Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Avogaro

Showing results (281-290 of 426) with videos related to

Pageof 43
Sort By:
Giornale Italiano Di Cardiologia (2006)|April 27, 2023
[Uncertainties in cardiovascular risk factors: sodium-glucose cotransporter 2 inhibitors for all diabetic patients with high cardiovascular risk and in all patients with renal insufficiency, regardless of albuminuria? Glucagon-like peptide-1 receptor agonists as a weapon against obesity?]Angelo Avogaro, Alberto Corsini, Gianfranco Sinagra, et al.
Giornale Italiano Di Cardiologia (2006)|November 24, 2020
[Grey zones on diabetes in cardiovascular disease. Expert opinion]Roberto Trevisan, Aurelia Grosu, Angelo Avogaro, et al.
The Journal of Clinical Endocrinology and Metabolism|December 24, 2015
Acute Effects of Linagliptin on Progenitor Cells, Monocyte Phenotypes, and Soluble Mediators in Type 2 DiabetesGian Paolo Fadini, Benedetta Maria Bonora, Roberta Cappellari, et al.
Journal of Diabetes Science and Technology|October 16, 2012
Continuous glucose monitoring accuracy results vary between assessment at home and assessment at the clinical research centerYoeri M Luijf, Angelo Avogaro, Carsten Benesch, et al.
American Journal of Physiology. Endocrinology and Metabolism|September 8, 2005
Brain oxygen utilization is unchanged by hypoglycemia in normal humans: lactate, alanine, and leucine uptake are not sufficient to offset energy deficitJeffrey M Lubow, Ivan G Piñón, Angelo Avogaro, et al.
Diabetes Care|February 10, 2007
Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic locationAngelo Avogaro, Carlo Giorda, Marina Maggini, et al.
The Journal of Clinical Endocrinology and Metabolism|August 27, 2010
Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic studyRiccardo C Bonadonna, Tim Heise, Christophe Arbet-Engels, et al.
Diabetes|April 30, 2020
Pharmacologic PPAR-γ Activation Reprograms Bone Marrow Macrophages and Partially Rescues HSPC Mobilization in Human and Murine DiabetesSerena Tedesco, Stefano Ciciliot, Lisa Menegazzo, et al.
Obesity (Silver Spring, Md.)|January 29, 2008
A polymorphism at the IL6ST (gp130) locus is associated with traits of the metabolic syndromeLucia Gottardo, Salvatore De Cosmo, Yuan-Yuan Zhang, et al.
Diabetes Care|November 1, 2012
Diabetes impairs stem cell and proangiogenic cell mobilization in humansGian Paolo Fadini, Mattia Albiero, Saula Vigili de Kreutzenberg, et al.
Pageof 43

Showing results (281-290 of 426) with videos related to

Sort By:
Pageof 43
Giornale Italiano Di Cardiologia (2006)|April 27, 2023
[Uncertainties in cardiovascular risk factors: sodium-glucose cotransporter 2 inhibitors for all diabetic patients with high cardiovascular risk and in all patients with renal insufficiency, regardless of albuminuria? Glucagon-like peptide-1 receptor agonists as a weapon against obesity?]Angelo Avogaro, Alberto Corsini, Gianfranco Sinagra, et al.
Giornale Italiano Di Cardiologia (2006)|November 24, 2020
[Grey zones on diabetes in cardiovascular disease. Expert opinion]Roberto Trevisan, Aurelia Grosu, Angelo Avogaro, et al.
The Journal of Clinical Endocrinology and Metabolism|December 24, 2015
Acute Effects of Linagliptin on Progenitor Cells, Monocyte Phenotypes, and Soluble Mediators in Type 2 DiabetesGian Paolo Fadini, Benedetta Maria Bonora, Roberta Cappellari, et al.
Journal of Diabetes Science and Technology|October 16, 2012
Continuous glucose monitoring accuracy results vary between assessment at home and assessment at the clinical research centerYoeri M Luijf, Angelo Avogaro, Carsten Benesch, et al.
American Journal of Physiology. Endocrinology and Metabolism|September 8, 2005
Brain oxygen utilization is unchanged by hypoglycemia in normal humans: lactate, alanine, and leucine uptake are not sufficient to offset energy deficitJeffrey M Lubow, Ivan G Piñón, Angelo Avogaro, et al.
Diabetes Care|February 10, 2007
Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic locationAngelo Avogaro, Carlo Giorda, Marina Maggini, et al.
The Journal of Clinical Endocrinology and Metabolism|August 27, 2010
Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic studyRiccardo C Bonadonna, Tim Heise, Christophe Arbet-Engels, et al.
Diabetes|April 30, 2020
Pharmacologic PPAR-γ Activation Reprograms Bone Marrow Macrophages and Partially Rescues HSPC Mobilization in Human and Murine DiabetesSerena Tedesco, Stefano Ciciliot, Lisa Menegazzo, et al.
Obesity (Silver Spring, Md.)|January 29, 2008
A polymorphism at the IL6ST (gp130) locus is associated with traits of the metabolic syndromeLucia Gottardo, Salvatore De Cosmo, Yuan-Yuan Zhang, et al.
Diabetes Care|November 1, 2012
Diabetes impairs stem cell and proangiogenic cell mobilization in humansGian Paolo Fadini, Mattia Albiero, Saula Vigili de Kreutzenberg, et al.
Pageof 43